Participants Dosed on Adessia in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa
Group in strategic collaboration with Divine Genes to offer genetic tests related to reproductive health in Malaysia and
overseas.
March 7, 2023
by PharmaSources
Biogen Welcomes NICE Announcement on TA375 as a Landmark Decision for UK Patients with Moderate Rheumatoid Arthritis
Biogen UK welcomes the decision by the National Institute for Health and Care Excellence (NICE) to broaden patient access to biologics, including biosimilars, to treat moderate rheumatoid arthritis (RA).
June 11, 2021
by firstwordpharma
EU authorises Celltrion’s adalimumab biosimilar Yuflyma
The European Commission has approved Celltrion Healthcare’s Yuflyma, a biosimilar to adalimumab – marketed by AbbVie as Humira.
February 19, 2021
by pharmatimes
Cadila Pharma launches Cadalimab (adalimumab biosimilar) for India
Cadila Pharmaceuticals announced the launch of adalimumab biosimilar under the brand name Cadalimab for the domestic market.
August 31, 2020
by expresspharma
The 2nd Chinese-Produced Adalimumab Biosimilar to be Approved for Marketing
From the current pattern in China, rather than the price war, Chinese-produced adalimumab biosimilars shall work on at least the following aspects: to strive to enter the NRDL to solve patients’ worries about payment; to strive for more indications to exp
January 8, 2020
by PharmaSources/Xiaoyaowan
Chinese Autoimmune Disease Drug Market: Which of the Competing Global Blockbuster Drugs Will Win?
Adalimumab has been “active” recently. Multiple adalimumab biosimilars are entering the harvest period in China following the arrival of China’s biosimilar era starting with ...
December 5, 2019
by PharmaSources/1°C
Breaking News! China’s Humira Biosimilar Produced by Bio-Thera to be Marketed Soon
The marketing application of Bio-Thera’s adalimumab (acceptance No.: CXSS1800018) has recently been under the “under approval” status, which is expected to be approved for marketing soon for treating ankylosing spondylitis (AS).
November 5, 2019
by PharmaSources/Caicai
Vedolizumab Beats Adalimumab for Ulcerative Colitis Remissions
In moderate-to-severe ulcerative colitis, vedolizumab is superior to adalimumab for achieving clinical remission and endoscopic improvement ...
September 26, 2019
by drugs
Patent litigation for adalimumab resolved in the US
AbbVie has announced that it has resolved its US HUMIRA (adalimumab) litigation with Boehringer Ingelheim.
May 29, 2019
by europeanpharmaceuticalreview
Boehringer Ingelheim axes biosimilars development outside US
Boehringer Ingelheim has said it has axed development of its biosimilars outside Europe, focusing instead on getting its Humira near-copy on the US market as soon as possible.
December 6, 2018
by pharmaphorum
NHS to save £300 million by switching to Humira biosimilars
NHS England has announced that the health service is set to save £300 million by switching to biosimilar versions of AbbVie’s best-selling anti-inflammatory drug Humira (adalimumab)
November 28, 2018
by pharmafile
Samsung and Bioepis launch third Humira biosimilar in Europe
Hot on the heels of Amgen, Samsung Bioepis and Biogen have announced the launch of their own biosimilar version of Abbvie’s best-selling drug Humira (adalimumab) in Europe.
October 19, 2018
by pharmafile